Home › Compare › TRVN vs QYLD

TRVN vs QYLD: Dividend Comparison 2026

TRVN yields 18018.02% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TRVN wins by $18633001307266260992.00M in total portfolio value
10 years
TRVN
TRVN
● Live price
18018.02%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18633001307266260992.00M
Annual income
$18,431,768,966,926,280,000,000,000.00
Full TRVN calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — TRVN vs QYLD

📍 TRVN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRVNQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRVN + QYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
TRVN pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRVN
Annual income on $10K today (after 15% tax)
$1,531,531.53/yr
After 10yr DRIP, annual income (after tax)
$15,667,003,621,887,337,000,000,000.00/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, TRVN beats the other by $15,667,003,621,887,337,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRVN + QYLD for your $10,000?

TRVN: 50%QYLD: 50%
100% QYLD50/50100% TRVN
Portfolio after 10yr
$9316500653633130496.00M
Annual income
$9,215,884,483,463,140,000,000,000.00/yr
Blended yield
98.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on TRVN right now

TRVN
Analyst Ratings
9
Buy
5
Hold
Consensus: Buy
Altman Z
-48.2
Piotroski
3/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRVN buys
0
QYLD buys
0
No recent congressional trades found for TRVN or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRVNQYLD
Forward yield18018.02% ✓11.92%
Annual dividend / share$2.00$2.04 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$18633001307266260992.00M ✓$25.4K
Annual income after 10y$18,431,768,966,926,280,000,000,000.00 ✓$5,659.31
Total dividends collected$18619711198521020416.00M ✓$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: TRVN vs QYLD ($10,000, DRIP)

YearTRVN PortfolioTRVN Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$1,812,502$1,801,801.80$10,352$1,192.36+$1.80M → TRVN
2$307,151,434$305,212,057.22$10,830$1,347.57+$307.14M → TRVN
3$48,667,022,851$48,338,370,816.14$11,460$1,539.07+$48667.01M → TRVN
4$7,210,053,431,136$7,157,979,716,686.14$12,275$1,777.84+$7210053.42M → TRVN
5$998,798,584,418,300$991,083,827,246,983.60$13,323$2,078.95+$998798584.40M → TRVN
6$129,380,351,742,642,780$128,311,637,257,315,230.00$14,667$2,463.34+$129380351742.63M → TRVN
7$15,672,057,030,122,314,000$15,533,620,053,757,686,000.00$16,396$2,960.57+$15672057030122.30M → TRVN
8$1,775,286,122,699,574,700,000$1,758,517,021,677,343,500,000.00$18,631$3,612.97+$1775286122699574.75M → TRVN
9$188,067,607,794,372,840,000,000$186,168,051,643,084,300,000,000.00$21,548$4,482.15+$188067607794372832.00M → TRVN
10$18,633,001,307,266,260,000,000,000$18,431,768,966,926,280,000,000,000.00$25,398$5,659.31+$18633001307266260992.00M → TRVN

TRVN vs QYLD: Complete Analysis 2026

TRVN — Stock

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Full TRVN Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this TRVN vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRVN vs SCHDTRVN vs JEPITRVN vs OTRVN vs KOTRVN vs MAINTRVN vs XYLDTRVN vs JEPQTRVN vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.